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A B S T R A C T
Background
Buprenorphine has been reported as an alternative to methadone and LAAM formaintenance treatment of opioid dependence, differing
results are reported concerning its relative effectiveness indicating the need for an integrative review.
Objectives
To evaluate the effects of buprenorphine maintenance against placebo and methadone maintenance in retaining patients in treatment
and in suppressing illicit drug use.
Search strategy
We searched the following databases up to 2001, inclusive: Cochrane Drugs and Alcohol Review Group Register, the Cochrane
Controlled Trials Register, MEDLINE, EMBASE, Current Contents, Psychlit, CORK [www. state.vt.su/adap/cork], Alcohol and Drug
Council of Australia (ADCA) [www.adca.org.au], Australian Drug Foundation (ADF -VIC) [www.adf.org.au], Centre for Education
and Information on Drugs and Alcohol (CEIDA) [www.ceida.net.au], Australian Bibliographic Network (ABN), Library of Congress
databases, available NIDA monographs, the College on Problems of Drug Dependence Inc. proceedings, the reference lists of all
identified studies and published reviews. Authors of identified RCT’s were asked about any other published or unpublished relevant
RCT.
Selection criteria
Randomised clinical trials of buprenorphine maintenance versus either placebo or methadone maintenance for opioid dependence.
Data collection and analysis
Reviewers evaluated the papers separately and independently, rating methodological quality of concealment of allocation; data were
extracted independently for meta-analysis and double-entered.
Main results
Thirteen studies met the inclusion criteria, all were randomised clinical trials, all but one were double-blind. Themethod of concealment
of allocation was not clearly described in 11 of the studies, otherwise methodological quality was good. Buprenorphine given in flexible
doses appeared statistically significantly less effective than methadone in retaining patient in treatment (RR= 0.82; 95% CI: 0.69-0.96).
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Low dose buprenorphine is not superior to low dose methadone. High dose buprenorphine does not retain more patients than low dose
methadone, but may suppress heroin use better. There was no advantage for high dose buprenorphine over high dose methadone in
retention (RR=0.79; 95% CI:0.62-1.01), and high dose buprenorphine was inferior in suppression of heroin use. Buprenorphine was
statistically significantly superior to placebo medication in retention of patients in treatment at low doses (RR=1.24; 95% CI: 1.06-
1.45), high doses (RR=1.21; 95% CI: 1.02-1.44), and very high doses (RR=1.52; 95% CI: 1.23-1.88). However, only high and very
high dose buprenorphine suppressed heroin use significantly above placebo.
Authors’ conclusions
Buprenorphine is an effective intervention for use in the maintenance treatment of heroin dependence, but it is not more effective than
methadone at adequate dosages.
P L A I N L A N G U A G E S U M M A R Y
Buprenorphine can reduce heroin use, although it is not as effective as methadone
Methadone is the most widely used replacement for heroin in medically-supported maintenance or detoxification programs. Two
other drugs are sometimes used to try and help lower their use of heroin, buprenorphine and LAAM (levo-alpha-acetylmethadol).
Buprenorphine is an opioid drug that is not as powerful as heroin and methadone, although the effects may last longer. It is easier to
withdraw from buprenorphine than methadone, and can be taken once every two days. The review of trials found that buprehnorphine
can reduce heroin use effectively, although it is not as effective as methadone.
B A C K G R O U N D
Heroin dependence is becoming increasingly prevalent, with asso-
ciated increases in the spread of infectious disease (e.g., HIV, hep-
atitis B andC) andoverdose deaths.One of themain forms of treat-
ment has been methadone maintenance treatment. As set out by
elsewhere (Mattick 1998, Mattick 2003), maintenance treatment
with oral methadone appears to be an effective and accepted inter-
vention for opioid (heroin) dependence, and it is widely used in
some countries. Yet, methadone maintenance treatment (MMT)
has a number of negative characteristics which potentially influ-
ence its effectiveness andwhich have led to an interest in alternative
pharmacotherapies and methods of treatment delivery (Mattick
1998). The negative aspects of methadone are set out below.
Methadone is a full opioid agonist at µ-receptors. Thus, one neg-
ative aspect of methadone is its potential to produce and/or main-
tain dependence on opioids, such that patients experience with-
drawal if a daily dose is missed, and detoxification can be a lengthy
and difficult process which can discourage patients from attempt-
ing withdrawal. Additionally, because of its full agonist action,
there is no ceiling to the level of respiratory depression or seda-
tion which methadone can induce, and methadone overdose can
therefore be fatal. Although it is a long-acting opioid, in some
countries and settings, the inconvenience of daily dosing and clinic
visits may be unattractive to clients, and restrictions imposed by
the daily dosing schedule on clients’ general lifestyle and on op-
portunities to sustain employment may also limit its acceptance
to heroin users. The provision of takeaway doses of methadone
results in problems of diversion of the drug for illicit use by those
not in treatment, although the extent of this problem varies across
countries. Finally, heroin users have developed their own “lore”
regarding methadone’s negative effects, although their views may
not always be accurate or favourable. Thus, despite its many ad-
vantages, methadone maintenance appears to have limited suit-
ability for some patients. These factors may restrict the ability of
methadone to attract certain users into treatment, and the exam-
ination of alternative medications to broaden the range of phar-
macotherapies been the focus of research in recent years.
There are a number of alternatives to methadone as a mainte-
nance agent in the management of opioid dependence. The most
promising of these involve pharmacotherapies which treat patients
with a pharmaceutical grade opioid which has a longer duration
of action than methadone. These include the opiate partial ago-
nist buprenorphine and the full agonist levo-alpha-acetylmethadol
(LAAM) (Mattick 1998) . This review focuses on the role of
buprenorphine as a maintenance therapy in the management of
opioid dependence.
Buprenorphine is a potent synthetic opioid analgesic initially used
for the management of acute pain. Pharmacologically, buprenor-
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phine causes morphine-like subjective effects and produces cross-
tolerance to other opioids. Unlike methadone and heroin (which
are full agonists), buprenorphine is a partial agonist and exerts
weaker opioid effects at opioid receptor sites. This partial agonist
action appears to make buprenorphine safer in overdose. Other
benefits of buprenorphine may include an easier withdrawal phase
and, because of the longer duration of action, the option of alter-
nate day dosing.
It was during the initial development of buprenorphine as an anal-
gesic in the 1970’s that its potential utility as a substitution agent
in the treatment of opioid dependence was recognised. Early work
(Jasinski 1978) using buprenorphine administered by the subcu-
taneous route, characterised it as an opioid with low physical de-
pendence liability with a minimal withdrawal syndrome. Subse-
quently, others (Fudala 1990) provided evidence that buprenor-
phine does produce a mild to moderate mu-agonist withdrawal
syndrome.) It was thought that at doses somewhat greater than
those used for analgesia, it could be used in the treatment of opioid
dependence (Jasinski 1978).
Evidence on the efficacy of buprenorphine has come fromplacebo-
controlled trials ( Johnson 1995a, Ling 1998), fixed dosing stud-
ies of buprenorphine versus methadone maintenance treatment
(Bickel 1988; Johnson 1992; Kosten 1993; Ling 1996; Fischer
1999; Uehlinger 1998) and variable dosing studies of buprenor-
phine versus methadone maintenance treatment (Strain 1994a;
Strain 1994b;Mattick 2003). Clinical trials conducted in the U.S.
showed buprenorphine to be superior to placebo medication, but
whenbuprenorphine andmethadonemaintenancewere compared
in a series of impressive studies using fixed doses of the drugs, the
results were mixed. Some of the fixed dose studies showed no dif-
ference in efficacy, whereas others showed superiority for metha-
done and yet others showed the reverse pattern. The investigators
in these fixed dose studies frequently concluded that the doses of
buprenorphine, or methadone, chosen were too low or that poor
induction regimes led to poor retention. A series of variable (or
flexible) dose studies have been conducted and shown essentially
equivalent results for the two drugs. Given the mixed results, it
seems particularly important to attempt a systematic integration of
the literature, and separately assessing the fixed and variable dose
studies and discussing the results in the light of the differing doses
and other individual trial features. Additionally, this review sepa-
rately summarises the available placebo-controlled trial results.
O B J E C T I V E S
The present systematic review had the objective of providing an
evaluation of the buprenorphine maintenance treatment in the
management of opioid dependence.
R E S U L T S
1. Selection of Studies/Participants/Interventions:
There were thirteen studies included in this review (2544 partici-
pants).
Characteristics of the participants were generally well described.
Majority of participants in these studies weremale, consistent with
the profile of the heroin dependant users generally. They tended
to be approximately 30 years of age, again consistent with what is
known about heroin users presenting for treatment.
The interventions ranged in duration from 6 weeks through to 52
weeks. By and large the interventions used clinically relevant doses
of medication, although as noted earlier a number of the studies
used fixed doses of medication and this created some limitations
in terms of generalisability to day-to-day clinical practice. Specif-
ically, in day-to-day clinical practice flexible dosing is used.
2. Quantitative Analysis
2a. Flexible Dose Buprenorphine versus Flexible Dose Methadone
As noted earlier, the flexible dose studies reported probably pro-
vide the best estimate of the likely impact of methadone and
buprenorphine in day-to-day clinical practice, as they mirror clin-
ical practice in terms of dose adjustments and in terms of the doses
employed in the studies. The six studies included in the flexible
dose buprenorphine versus flexible dose methadone analysis (837
participants) showed that methadone was more likely to retain
patients than buprenorphine (six studies, 837 participants; RR=
0.82; 95% CI: 0.69-0.96). The Chi-square test for heterogeneity
was not significant. Inspection of the relative risks for retention in
treatment for these six flexible dose studies showed two studies had
significant poor retention for buprenorphine, but the other four
studies showed no statistical significant difference. While there
was a difference in retention favouring methadone, turning to the
effect of buprenorphine and methadone on drug use, the flexible
dose studies showed no significant difference between the two in-
terventions in terms of heroin use, based on results of morphine
urinanalysis (six studies, 837 participants; SMD= -0.12; 95% CI:
-0.26- 0.02), or in terms of self-reported heroin use (two studies,
326 participants; SMD= -0.10; 95% CI: -0.32- 0.12). Similarly,
there was no statistically significant difference between the flexi-
ble dose methadone and buprenorphine trials in terms of cocaine
positive urines (five studies, 779 participants; SMD= 0.11; 95%
CI: -0.03 - 0.25) or benzodiazepine positive urines (four studies,
669 participants; SMD= 0.11; 95% CI: -0.04-0.26).
In the one study that reported on criminal activity, there was no
statistically difference between the buprenorphine and methadone
groups (SMD= -0.14; 95% CI: -0.41- 0.14).
2b. Low Dose Buprenorphine versus Low Dose Methadone
The comparison of low dose buprenorphine and low dose metha-
done (two studies, 121 participants) indicated no statistically sig-
nificant difference in retention in treatment (RR = 0.74; 95% CI:
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0.52-1.06), nor was there evidence of differences inmorphine pos-
itive urines and cocaine positive urines based on one trial. There
was no difference in self-reported heroin use (one study with 44
participants; SMD= -0.28; 95% CI: -0.35- 0.90).
2c. Low Dose Buprenorphine versus High Dose Methadone
When low dose buprenorphine is compared to high dose meth-
adone (2 RCTs, 120 participants) there was no statistical differ-
ence in retention in treatment (RR= 0.69; 95%CI: 045-1.06).
The trials involved did not show heterogeneity. The results show
that low dose buprenorphine is not more effective than high dose
methadone in retaining patients in treatment, and it is not supe-
rior to high dose methadone in suppressing heroin use as indexed
by the extent of morphine positive urines (one study, 57 partici-
pants; SMD= 0.88; 95% CI: 0.33 - 1.42). However, the overall
effect is only based on one study, as data from the second study
(Kosten 1993) concerning the urine results were not available for
this review. There was, also, no statistically significant difference
of the effect of low dose buprenorphine and high dose methadone
beyond the effect of on cocaine, as shown from data on cocaine
positive urines (one study, 57 participants; SMD= -0.08; 95% CI:
-0.60- 0.44).
There was no statistically significant difference in self-reported
heroin use (one study, 38 participants; SMD= -0.06; 95% CI: -
0.70- 0.58). However, the results from Schottenfeld 1997 on self-
reported heroin use, which could not be included in this meta-
analysis, did show a significant advantage for high dose methadone
(65mg) over low dose buprenorphine (4mg).
2d. High Dose Buprenorphine versus Low Dose Methadone
When comparing high dose buprenorphine there was one study
which favoured high dose buprenorphine in terms of retention,
one study that favoured low dose methadone, and two studies
showed no statistically significant difference. The test for hetero-
geneity was significant for the retention data (chi-square=11.47,
df=3, p=0.0095) therefore no summarymeasure is provided.How-
ever, high dose buprenorphinewas superior to lowdosemethadone
in terms of heroin use as shown from morphine positive urines
(three studies, 317 participants; SMD= -0.23; 95%CI: -0.45--
0.01), but again the chi-square test for heterogeneity was signifi-
cant (p=0.041), even though direction of the estimateswere homo-
geneous. In terms of cocaine positive urines, no benefit was shown
for high dose buprenorphine compared with low dose methadone,
based on only one study (59 participants).
There was no difference in self-reported heroin use (one study, 37
participants; SMD= -0.64; 95% CI: -0.06- 1.33).
2e. High Dose Buprenorphine versus High Dose Methadone
Comparing high dose buprenorphine and high dose methadone,
the data on retention in treatment (5 RCTs, 449 participants)
showed no statistical difference between the two interventions
(RR=0.79; 95% CI:0.62-1.01), but suggest that high doses of
buprenorphine are less likely to retain patients than high dose
methadone. The trials involved in this comparison (Johnson 1992,
Kosten 1993, Ling 1996, Pani 2000, Schottenfeld 1997) did not
show any evidence of heterogeneity. High dose buprenorphine
was also significantly less able to suppress heroin use as shown by
morphine positive urines (3 studies, 314 participants: SMD=0.27;
95%CI: 0.05-0.50) while no statistically significant difference was
found in terms of cocaine use based on the cocaine urine analysis
results of only one study (57 participants).
There was no difference in self-reported heroin use (two studies,
74 participants; SMD= -0.02; 95% CI: -0.48- 0.45). This lack of
significance is consistent with the results from Schottenfeld 1997
on self-reported heroin use, which could not be included in this
meta-analysis, and which did not show a significant advantage
for high dose methadone (65mg) over high dose buprenorphine
(12mg).
2f. Low dose buprenorphine maintenance versus placebo
Turning to the results on the two trials (487 participants) compar-
ing low dose buprenorphine (2mg or 4 mg) versus placebo med-
ication (0mg or 1mg, respectively) (Johnson 1995a, Ling 1998),
the results showed a benefit for low dose buprenorphine above
placebo in terms of retaining patients in treatment (RR=1.24; 95%
CI: 1.06-1.45). However, low dose buprenorphine patients had
no less heroin use as indexed by morphine positive urines, co-
caine positive urine results, and benzodiazepine positive urines ,
although these latter two results came from only one of the two
trials (Johnson 1995a).
2g. High dose buprenorphine maintenance versus placebo
The results on the two trials (463 participants) comparing high
dose (8mg) buprenorphine versus placebo medication (Johnson
1995a, Ling 1998), the results showed a benefit for buprenorphine
above placebo in terms of retaining patients in treatment (RR=
1.21; 95% CI: 1.02-1.44). Not only were patients better retained
by buprenorphine but they had less heroin use as indexed by mor-
phine positive urines. There was an advantage for placebo in terms
of cocaine positive urine results, but this is based on only one study
(Johnson 1995a). By way of contrast, buprenorphine was superior
to placebo in terms of its ability to suppress benzodiazepine use,
again this result coming from one trial (Johnson 1995a).
2h. Very high dose buprenorphine maintenance versus placebo
Finally, turning to the one trial (366 participants) comparing
very high dose (16mg) buprenorphine versus placebo medication
(Ling 1998), the results showed a benefit for buprenorphine above
placebo in terms of retaining patients in treatment (RR=1.52; 95%
CI: 1.23-1.88). Not only were the patients in this single trial better
retained by buprenorphine, but they had less heroin use when re-
ceiving 16mg of buprenorphine than placebo patients as indexed
by morphine positive urines.
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Other measures (e.g. use of other drugs, physical health, and psy-
chological health) were too infrequently and irregularly reported
in the literature to be usefully integrated in the quantitative part
of this review.
D I S C U S S I O N
Buprenorphine is superior to placebo in terms of retention based
on the large study by Ling 1998 and the study by Johnson 1995a,
and it is superior in terms of its ability to suppress heroin use.
When compared with methadone, the results of the meta-analysis
indicate that methadone is statistically significantly better able to
retain patients than buprenorphine in flexible dosing approaches,
the difference being slight in favour of methadone. Methadone is
better able to suppress heroin use than buprenorphine, especially if
high-dose methadone is used (and vice-versa). Similar conclusions
have been reached by other recent meta-analytic reviews of these
treatments (West 2000; Barnett 2001).
One explanation which has been advanced by authors in some of
the studies included here for the poorer retention in buprenor-
phine treatment (Fischer 1999, Petitjean 2001) is that they in-
ducted patients too slowly onto buprenorphine and this was the
cause of the poorer retention in that medication group. It is pos-
sible that retention is affected by too slow induction, and given
the apparent relative safety of buprenorphine it may be possible
to induct people to higher doses at a more rapid rate and to over-
come the problem of slightly poorer retention for buprenorphine
compared with methadone. However, there are a number of other
possible explanations for the poorer retention on buprenorphine
than methadone. In particular, it may well be that buprenorphine,
being a partial agonist, does not retain people because it does not
have a full opioid effect and is less satisfying to patients. Another
possibility is that patients in the initial stages of dosing who have
recently ingested heroin suffer a mild withdrawal syndrome by
virtue of buprenorphine (a partial agonist) displacing heroin (a
full agonist) from opioid receptors in the central nervous system,
and this mild withdrawal may lead patients to leave treatment. A
further possibility is that buprenorphine is simply easier to with-
draw from and, on that basis, patients are more at liberty to leave
treatment without the severe withdrawal syndrome that can ac-
company methadone withdrawal. Of course, these factors may all
act together to cause buprenorphine to have a slightly poorer out-
come in terms retention than methadone. Future research should
be undertaken to address this particular issue.
These results show that, despite the effectiveness of buprenorphine
when compared with placebo, when methadone is given in high
doses buprenorphine is not a better treatment. These findings
could be taken to suggest that buprenorphine will be inferior to
methadone in day-to-day practice, but we point out that some of
doses used in the high dose methadone conditions are rarely used
in day-to-day clinical practice. If it were possible to get clinicians
and patients to agree to prescribe and take high dose methadone
then the clinical implication of this may be important, but the
reality is that most often methadone is prescribed in the range of
an average of 50 to 60 milligrams. At this level, as shown in the
flexible dose studies earlier, there does not appear to be any reliable
difference in heroin use between methadone and buprenorphine,
overall.
The clinical trials represented in this review are of reasonable qual-
ity, and whilst many of them did not fully explain how randomi-
sation was concealed, they appear to have used doses which are
clinically relevant and to have treated patients for significant pe-
riods of time. Based on the nature of the trials, it would appear
the external validity or generalisability of the results is quite good,
particularly from those trials which have used large sample sizes
and adequate doses.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The implication of the results of the meta-analytic review con-
ducted and reported herein are clear for clinical practice. Buprenor-
phine is an effective treatment for heroin use in a maintenance
therapy approach compared with placebo. However, methadone
maintenance treatment at high dose is associated with higher rates
of retention in treatment and better suppression of heroin than
buprenorphine maintenance treatment. Buprenorphine mainte-
nance should be supported as amaintenance treatment, onlywhere
higher doses of methadone cannot be administered. The reasons
for not applying the best available treatment should be investi-
gated rather than promoting less effective treatment approaches.
Given buprenorphine’s different pharmacological properties, it
may have advantages in some settings and under some policies
where its relative safety and alternate-day administration are useful
clinically compared to methadone.
Implications for research
Overall, the quality of the studies included in this meta-analytic
review was quite good. The trials did use sample sizes which varied
from relatively small to quite large, but they were mostly double-
blind trials. There does not appear to be any need for further ran-
domised control trials of the relative efficacy of methadone com-
pared with buprenorphine. There does appear to be a need to un-
dertake studies which will clarify retention in the first few weeks
or months of treatment in buprenorphine versus methadone. One
way of addressing this issue would be to compare a standard in-
duction as used in some of the trials reported herein with a rapid
induction onto buprenorphine, with the potential to have a fur-
ther comparison of induction onto methadone. Problems in the
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methods of induction onto buprenorphine within the trials anal-
ysed might partly explain the inferiority of buprenorphine shown
in this review. It would be ideal if such a trial were to be conducted
under double blind conditions, particularly in terms of the rapid
versus standard induction onto buprenorphine. Other outcome
measures such as self-reported drug use, criminal activity, physical
health, and psychological health which were too infrequently and
irregularly reported in the literature to be analysed in the current
review could be included in future studies.
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